Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Zendy

Nicholas C. Turner | Zendy; Dennis J. Slamon | Zendy; Jungsil Ro | Zendy; Igor Bondarenko | Zendy; SeockAh Im | Zendy; Norikazu Masuda | Zendy; Marco Colleoni | Zendy; Angela DeMichele | Zendy; Sherene Loi | Zendy; Sunil Verma | Zendy; Hiroji Iwata | Zendy; Nadia Harbeck | Zendy; Sibylle Loibl | Zendy; Fabrice André | Zendy; Kathy Puyana Theall | Zendy; Xin Huang | Zendy; C. Giorgetti | Zendy; Cynthia Huang Bartlett | Zendy; Massimo Cristofanilli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Author(s) -

Nicholas C. Turner,

Dennis J. Slamon,

Jungsil Ro,

Igor Bondarenko,

SeockAh Im,

Norikazu Masuda,

Marco Colleoni,

Angela DeMichele,

Sherene Loi,

Sunil Verma,

Hiroji Iwata,

Nadia Harbeck,

Sibylle Loibl,

Fabrice André,

Kathy Puyana Theall,

Xin Huang,

C. Giorgetti,

Cynthia Huang Bartlett,

Massimo Cristofanilli

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1810527

Subject(s) - fulvestrant , palbociclib , medicine , hazard ratio , oncology , placebo , breast cancer , metastatic breast cancer , aromatase inhibitor , cancer , gynecology , confidence interval , estrogen receptor , tamoxifen , pathology , alternative medicine

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis of overall survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research